Aetna may provide coverage for the following weight loss injections when medically necessary and with prior authorization: Approved for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity like type 2 diabetes, high blood pressure, or sleep apnea
Additional research is required to further assess the safety and efficacy of CT-388 in larger, more diverse populations and to determine its long-term effects on weight management, glycemic control, and cardiovascular outcomes
The most common side effects of Wegovy may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat
In 2026, 82% require it